Indeed, the targeted DRD2 gene, a dopamine receptor, shows increased expression in many tumors [48] and its inhibition demonstrated effectiveness in suppressing the proliferation of endometrial cancer cells, as well as reducing tumor growth and metastatic potential [49]. The gene discussed is DRD2; the disease is endometrial cancer.